Shares of Pharming Group NV (OTCMKTS:PHGUF – Get Free Report) hit a new 52-week low on Thursday . The stock traded as low as $1.10 and last traded at $1.10, with a volume of 5000 shares traded. The stock had previously closed at $1.15.
Pharming Group Stock Performance
The company has a current ratio of 2.63, a quick ratio of 2.06 and a debt-to-equity ratio of 0.40. The firm’s fifty day moving average is $1.24 and its 200 day moving average is $1.47. The company has a market cap of $738.18 million, a PE ratio of 91.67 and a beta of 0.46.
Pharming Group Company Profile
Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.
Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.
Recommended Stories
- Five stocks we like better than Pharming Group
- MarketBeat Week in Review – 08/10 – 08/14
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
